Trenbolone enanthate has never been officially registered as a medicinal product for humans, so much less is known about its pharmacokinetics than that of testosterone. Most of the "accurate" figures floating around the forums are extrapolations. The editors analysed what is really known from the scientific literature about the absorption, transformation and excretion of this substance, and what remains conjecture.
Why pharmacokinetic data are limited
Pharmacokinetics describes the four stages of a molecule's life in the body: absorption, distribution, metabolism, and excretion. For registered drugs, these parameters are determined in formal clinical trials on volunteers, and the results are included in the instructions. No such instructions exist for trenbolone enanthate: this form has not been approved by any regulator for either humans or animals.
Trenbolone as a compound was studied primarily in veterinary medicine. Its acetate ester has been included in cattle fattening implants for decades, so the scientific data on trenbolone kinetics have come mostly from animals, as well as from anti-doping laboratory studies that looked at metabolites in the urine of volunteers after a single dose of small amounts of the substance.
The only form of trenbolone once approved for use in humans was trenbolone hexahydrobenzylcarbonate, sold in France until 1997. Even for him, detailed pharmacokinetic data are almost not presented in the modern English-language literature. Therefore, the editors emphasize that the figures about the "half-life of enanthate" are estimates by analogy with testosterone enanthate, and not the results of measurements.
Such a situation is of practical importance for safety. When there is no data on the actual concentration of a substance in the blood, it is impossible to predict how long its effects last, when side effects disappear, and how long it takes for the hormonal system to begin to recover. Uncertainty is aggravated by the fact that the products of the illegal market often do not correspond to the declared composition.
Enanthate ester and depot release
Enanthate is a heptanoic acid residue attached to the 17β-hydroxyl group of trenbolone. The ester makes the molecule more lipophilic: after intramuscular injection of the oil solution, it slowly moves from the oil depot to the water environment of the tissues. Further, blood and tissue esterases cleave the ester, and already free trenbolone interacts with the receptors.
Calculation by molecular weight shows that trenbolone itself accounts for about 71% of the mass of trenbolone enanthate. For acetate, this share is about 87%, and for hexahydrobenzylcarbonate - about 66%. Therefore, the same number of milligrams of different esters contains a different amount of active substance, which is often forgotten when comparing drugs.
| Trenbolone form | Ester | Share of trenbolone in molecular weight | Status |
|---|---|---|---|
| Trenbolone acetate | Acetic acid (2 C atoms) | ~87% | Veterinary implants |
| Trenbolone enanthate | Heptanoic acid (7 C atoms) | ~71% | Never been registered |
| Trenbolone hexahydrobenzylcarbonate | Cyclohexyl methyl carbonate | ~66% | Former human medicine in France; withdrawn in 1997 |
By analogy with testosterone enanthate, for which the half-life from the depot is estimated to be approximately 4-5 days, for trenbolone enanthate, a similar order of magnitude is usually assumed - several days. However, this analogy is close: the core of trenbolone differs in lipophilicity from testosterone, and the rate of release also depends on the oil base, volume and injection site.
Free trenbolone itself, like most steroids, has a short plasma half-life of the order of hours. That is why the ester, and not the nucleus of the molecule, determines the duration of the drug's action. When the depot is exhausted, the concentration of trenbolone falls quite quickly, but the effects of its action, in particular the suppression of the hormonal axis, persist much longer.
Trenbolone metabolism
Trenbolone belongs to the 19-norsteroids and has three conjugated double bonds in the rings of the steroid nucleus (positions 4, 9 and 11). This structure makes it resistant to aromatase: unlike testosterone, it does not turn into oestradiol. In addition, trenbolone is not enhanced by the enzyme 5α-reductase in the same way as testosterone, which is converted to the more active dihydrotestosterone.
The main routes of metabolism described in anti-doping and veterinary studies are epimerization at position 17 to form 17α-trenbolone (epitrenbolone), oxidation to trenedione, and subsequent formation of conjugates with glucuronic acid and sulfate. In cattle, epitrenbolone is the dominant metabolite and is monitored in meat and liver.
- 17β-trenbolone is an active parent form that binds to androgen and progesterone receptors.
- 17α-trenbolone (epitrenbolone) is an epimer with much lower biological activity, one of the key markers in urine.
- Trenedione is a product of oxidation of the 17-hydroxyl group.
- Glucuronides and sulfates are water-soluble conjugates in the form of which metabolites are excreted by the kidneys.
A review by Schänzer (Schänzer, 1996), devoted to the metabolism of anabolic steroids, emphasizes that trenbolone is characterized by a relatively small number of metabolites compared to other steroids, and part of the parent substance is excreted unchanged or epimerized. This made early analytical control difficult, because trenbolone does not lend itself well to classical gas chromatography.
The liver remains the main organ of metabolism, but the injectable form bypasses the "first pass" characteristic of tablets. This does not mean complete safety for the liver: the load on it, as well as on the kidneys, depends on the total amount of the substance, the duration of use and concomitant factors, in particular alcohol and other drugs.
Derivation and duration of detection
Conjugated metabolites of trenbolone are excreted mainly with urine, a smaller part with bile. The rate of excretion is primarily determined by how long the ester depot works: while a new substance is coming from the injection site, both the original compound and its metabolites are found in the urine.
The time during which traces of trenbolone can be detected does not coincide with the time of its pharmacological action. Current methods of liquid chromatography with tandem mass spectrometry allow the detection of very low concentrations of metabolites, and the duration of detection for long esters can be many weeks. It is impossible to give an exact number: it depends on the amount of the substance, the duration of use and the sensitivity of the method.
Trenbolone in all forms is listed on the World Anti-Doping Agency (WADA) Prohibited List under Section S1 Anabolic Agents - it is prohibited at any time, both in-competition and out-of-competition. The editors deliberately do not discuss any "withdrawal windows" in the context of doping control: any detection is an anti-doping rule violation.
A separate issue is urine discolouration, which is often associated with trenbolone. Darkening or a reddish tint of urine cannot be considered a "normal feature of the drug": such changes may indicate dehydration, blood in the urine or destruction of muscle tissue and require laboratory examination.
Factors that change kinetics
Even for registered testosterone esters, individual concentration fluctuations are significant. For illegal trenbolone enanthate, the uncertainty is even greater because there are no production standards. Laboratory analyzes of the withdrawn drugs repeatedly revealed inconsistency with the declared concentration, replacement of the active substance or impurities.
Release from the depot is influenced by the composition of the oil, the presence of solvents (benzyl benzoate, benzyl alcohol), the injection volume, and the blood supply to the muscle. A large volume of solution spreads more slowly, and absorption occurs faster in a well-supplied muscle. Body weight and the proportion of adipose tissue are also important.
Metabolism depends on liver and kidney function, genetic features of conjugation enzymes and interaction with other substances. People who take multiple steroids, alcohol, or medications that affect liver enzymes may have a completely different concentration profile than the one described in the popular tables.
Finally, cumulation: with repeated administrations of a substance with a long ester, blood levels build up over several weeks until equilibrium is established. Because of this, side effects may appear and worsen with a delay, and after stopping, they may not disappear immediately. This effect is important to consider when evaluating any changes in well-being and analyses.
Editorial conclusions
The pharmacokinetics of trenbolone enanthate are known primarily from veterinary and anti-doping studies, not from clinical trials. The popular half-life numbers are just estimates by analogy with testosterone enanthate.
Trenbolone core is not aromatized and not enhanced by 5α-reductase; the main metabolites are epitrenbolone, trenedione and their conjugates, which are excreted in the urine. Modern methods allow detecting these compounds for a long time.
The lack of standardization of illegal drugs makes the real-world kinetics unpredictable, and the long ester cumulation means that effects and side effects can last longer than a person expects.
The editors recommend that you also read our materials on the side effects of trenbolone enanthate, on its effects on the cardiovascular system and on the tests that should be monitored.
List of used literature
- Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001â1020.
- Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): a potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids. 2010;75(6):377â389.
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502â521.
- Meyer HH. Biochemistry and physiology of anabolic hormones used for improvement of meat production. APMIS. 2001;109(1):1â8.
- Nieschlag E, Behre HM, Nieschlag S (eds). Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012.
- World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; акÑÑалÑна ÑедакÑÑÑ.
